GlassScriptPhysician profile
Palak Patel
NPI 1548728033
$5,801.72
in general payments reported to CMS, 2019-2025
23 companies · $2,673 in 2025
The $2,673 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $240 · 2021: $466 · 2022: $836 · 2023: $692 · 2024: $893 · 2025: $2,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Travel and Lodging: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.97 |
| Travel and Lodging | $1,677.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $1,998.86 | 2025 | Syfovre |
| Alcon Vision LLC | $905.38 | 2021-2025 | Clareon, Unity, Hydrus Microstent |
| Sight Sciences, INC. | $357.29 | 2021-2022 | |
| Abbvie INC. | $339.37 | 2022-2025 | |
| Genentech USA, INC. | $300.97 | 2023-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $296.56 | 2023-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $223.89 | 2023-2025 | Izervay |
| Carl Zeiss Meditec USA, INC. | $206.04 | 2023-2025 | Iolmaster 700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.28 | 2020-2021 | |
| Ocular Therapeutix, INC. | $172.20 | 2024 | |
| Genentech, INC. | $141.15 | 2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $138.35 | 2022-2025 | Stellaris |
| Dutch Ophthalmic, USA | $135.24 | 2024 | Eva, Combined Machine, Tissueblue |
| Allergan, INC. | $117.07 | 2020-2021 | |
| Glaukos Corporation | $72.31 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $37.51 | 2023 | Tepezza |
| Ethicon US, LLC | $31.50 | 2023 | Stratafix |
| Spark Therapeutics, INC. | $30.74 | 2022 | |
| Dompe US, INC. | $29.09 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $23.81 | 2021 | |
| Harrow Eye, LLC | $23.07 | 2024 | Iheezo |
| Aerie Pharmaceuticals, INC. | $20.64 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.